Content area
Full Text
Cancer Chemother Pharmacol (2014) 73:943950
DOI 10.1007/s00280-014-2425-9
ORIGINAL ARTICLE
Factor associated with failure to administer subsequent treatment after progression in the rstline chemotherapy in EGFRmutant nonsmall cell lung cancer: Okayama Lung Cancer Study Group experience
Abstract
Purpose Early administration of both epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and cytotoxic chemotherapy is crucial for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. We investigated the effect of rst-line administration of these therapies on subsequent therapy in NSCLC patients.
Methods This study enrolled 63 consecutive patients with advanced EGFR-mutant NSCLC and good performance status (PS) and who underwent rst-line EGFR-TKI therapy or standard cytotoxic chemotherapy and then had progressive disease, from 2007 to 2011. The ability of each
This article was presented in the 48th annual meeting of American Society of Clinical Oncology (ASCO) in the general poster session.
Electronic supplementary material The online version of this article (doi:http://dx.doi.org/10.1007/s00280-014-2425-9
Web End =10.1007/s00280-014-2425-9 ) contains supplementary material, which is available to authorized users.
Y. Kato K. Hotta (*) A. Sato E. Ichihara K. Kudo M. Tabata M. Tanimoto K. Kiura
Department of Respiratory Medicine, Okayama University Hospital, 2-5-1, Shikata-cho, Kitaku, Okayama 700-8558, Japan e-mail: [email protected]
N. Takigawa
Department of Internal Medicine 4, Kawasaki Medical School, Okayama, Japan
N. Nogami T. Kozuki T. Shinkai
Department of Medicine, NHO Shikoku Cancer Center, Matsuyama, Japan
I. Oze
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
Yuka Kato Katsuyuki Hotta Nagio Takigawa Naoyuki Nogami Toshiyuki Kozuki Akiko Sato Eiki Ichihara Kenichiro Kudo Isao Oze Masahiro Tabata Tetsu Shinkai Mitsune Tanimoto Katsuyuki Kiura
Received: 9 September 2013 / Accepted: 23 February 2014 / Published online: 16 March 2014 Springer-Verlag Berlin Heidelberg 2014
patient to receive the other therapy after rst-line treatment failure was assessed.
Results In the rst-line setting, 23 and 40 patients received EGFR-TKI therapy and cytotoxic chemotherapy, respectively. At relapse, the EGFR-TKI therapy group showed more frequent PS deterioration (p = 0.042) and greater likeli
hood of symptomatic central nervous system (CNS) relapse (p = 0.093) compared with the cytotoxic chemotherapy
group. Nine (39 %) of 23 patients initially receiving EGFRTKI therapy could not receive standard cytotoxic therapy after progression mainly due to symptomatic CNS relapse. Only one (3 %) of 40 initially treated...